biotechFinancial Times — Technology· 7/16/2026, 6:12:05 PM★ 8.0
Dassault Systèmes in talks to buy drug trial software company for about $2bn
Dassault Systèmes in talks to buy drug trial software company for about $2bn Subscribe to unlock this article Try unlimited access Only ₩1000 for 4 weeksThen ₩79999 per month. Complete digital access to quality FT journalism on any device. Cancel anytime during your trial. Explore more offers. Explore our full range of subscriptions. For individuals Discover all the plans currently available in your country
💡 AI analysis: Dassault Systèmes’ ~$2B deal for a drug testing software firm rapidly consolidates the life sciences digital twin market and forces structural revenue shifts in traditional CRO models.
Related entities